Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors

Abstract

rh-Endo was safe and well tolerated. rh-Endo pharmacokinetic profiles achieved area under the concentration-time curves associated with activity in preclinical models. Evidence of minor antitumor activity was observed and further studies are indicated.